Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER plus endocrine-resistant breast cancer xenograft models

被引：1
|
作者：
Shomali, Maysoun
Guo, Zhuyan
Cheng, Jane
Sullivan, Amy
El-Ahmad, Youssef
Sun, Fangxian
Sidhu, Sukhvinder
Lee, Joon Sang
Cai, Hui
Pollard, Jack
Debussche, Laurent
Soria, Chris
Bouaboula, Monsif
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P4-02-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-08
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER plus breast cancer models resistant to CDK4/6 inhibitors
    Patel, Hitisha K.
    Tao, Nianjun
    Lee, Kyung-Min
    Huerta, Mariela
    Arlt, Heike
    Mullarkey, Tara
    Troy, Steven
    Arteaga, Carlos L.
    Bihani, Teeru
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [2] Elacestrant (RAD1901) demonstrates anti-tumor activity in models resistant to CDK4/6 inhibitors
    Patel, H.
    Tao, N.
    Arlt, H.
    Bihani, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Proteogenomic characterization of CDK4/6 inhibitor-resistant ER plus breast cancer
    Chen, Christopher T.
    Leshchiner, Ignaty
    Martin, Liz
    Kane, Harry
    Rhrissorrakrai, Kahn
    Utro, Filippo
    Levovitz, Chaya
    Gillette, Michael
    Satpathy, Shankha
    Pinto, Christopher
    McLoughlin, Daniel
    Allen, Read
    Danysh, Brian P.
    Slowik, Kara
    Jacobs, Raquel A.
    Carr, Steven
    Parida, Laxmi
    Getz, Gad
    Juric, Dejan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [4] Metabolic reprogramming of ER plus breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Parri, Matteo
    Malorni, Luca
    Di Leo, Angelo
    Chiarugi, Paola
    Morandi, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 529 - 530
  • [5] Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
    Hitisha K. Patel
    Nianjun Tao
    Kyung-Min Lee
    Mariela Huerta
    Heike Arlt
    Tara Mullarkey
    Steven Troy
    Carlos L. Arteaga
    Teeru Bihani
    Breast Cancer Research, 21
  • [6] Anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells
    Kishino, E.
    Ogata, R.
    Saitoh, W.
    Koike, Y.
    Ohta, Y.
    Kanomata, N.
    Moriya, T.
    Kurebayashi, J.
    BREAST, 2019, 44 : S28 - S28
  • [7] Combining OP-3136, a KAT6 inhibitor, with endocrine therapy and CDK4/6 inhibitor enhances anti-tumor activity in ER+/HER2-breast cancer models
    Palanisamy, G.
    Barratt, S.
    Hope, C.
    Robello, B.
    Pena, G.
    Goyal, M.
    Venkateshappa, C.
    Ng, R.
    Ramachandra, M.
    Myles, D.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S89 - S89
  • [8] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [9] Brain penetrant CDK4/6 inhibitor PRT3645 demonstrates anti-tumor activity and enhances survival in glioblastoma and breast cancer brain metastasis models
    Juvekar, Ashish
    Zhang, Yang
    Buesking, Andrew
    Wang, Min
    Rominger, Dave
    Rager, Joseph
    Ruepp, Stefan
    Gallagher, Kirsten
    Zou, Yue
    Cowart, Miles
    Wu, Xiaowei
    Pawley, Sarah
    Holmes, Ryan
    Gowen-MacDonald, William
    Vaddi, Kris
    Combs, Andrew
    Ruggeri, Bruce
    Scherle, Peggy
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer
    Luo, Linjie
    Navarro-Yepes, Juliana
    Wang, Yan
    Bui, Tuyen
    Kettner, Nicole
    Tripathy, Debu
    Hunt, Kelly
    Faia, Kerrie
    Keyomarsi, Khandan
    CANCER RESEARCH, 2024, 84 (09)
12345